Form D · Pharmaceuticals

Silver Creek Pharmaceuticals, Inc.

San Francisco, CA · CIK 0001691988

Offering snapshot reported Feb 14, 2022 · SEC filing

Reported sold
$9.15M
Offering amount: $25M
Investors reported
22
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 31, 2022
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 14, 2022Initial$9,150,000No comparison22SEC filing
Dec 19, 2016Initial$3,420,106No comparison13SEC filing

Offering details

Securities
Equity, Debt
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-433467
The Issuer is offering up to $25,000,000 in principal amount of convertible promissory notes. This Form D is also intended to cover the underlying equity securities.

Source: Form D, filed Feb 14, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Mark Agne Director
Ross Breckenridge Director, Executive
Lakhmir Chawla Executive
Michael Fairbanks Director
Kris Kuchenbecker Executive
James D. Marks Director
Thomas J. Murtagh Director
Tom Murtagh Director
Ulrik Nielsen Director
Birgit Schoeberl Director, Executive
Nick Taylor Director
Timothy Throsby Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
409 Illinois Street
San Francisco, CA, 94158